Further, despite cell-to-cell variations in p53 dynamics driving heterogeneous tumor cell behavior under cancer therapies (Batchelor and Loewer, 2017; Friedel and Loewer, 2022; Paek et al, 2016; Xie et al, 2022; Yang et al, 2018; Wu et al, 2017), the potential to synchronize these dynamics, to our knowledge, remains unexplored. The gene discussed is TP53; the disease is neoplasm.